NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
    India

    DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years

    DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
    Written by Ramya Patelkhana
    Edited by Abhishek Hari
    Apr 26, 2022, 04:44 pm 3 min read
    DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
    Two COVID-19 vaccines cleared by the DCGI for use in children between five and 12 years of age.

    In a significant move, the Drugs Controller General of India (DCGI) on Tuesday cleared two COVID-19 vaccines for use in children aged between five and 12 years. The country's apex drugs regulator has granted emergency use authorization to Bharat Biotech's COVAXIN for administration to kids in the 6-12 years age group and Biological E's Corbevax for the 5-12 age group. Here are more details.

    Why does this story matter?

    • The development comes as India witnesses a gradual increase in COVID-19 cases, especially in Delhi, Haryana, Uttar Pradesh, Mizoram, and Maharashtra.
    • The move assumes significance as a rise in infections in children has been observed in recent weeks.
    • To recall, the Centre launched vaccinations for adolescents aged 15-18 years on January 3, 2021. Last month, the drive was expanded to children aged 12-14 years.

    DCGI's approval follows expert panel's recommendations

    The DCGI's move comes after the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) sent its recommendations to the drugs regulator, according to reports. The SEC on COVID-19 had reviewed the EUA applications submitted by Bharat Biotech and Biological E for use in 6-12 years and 5-12 years age groups, respectively, last week.

    Vaccines authorized for usage after severe scrutiny

    The DCGI has reportedly asked Bharat Biotech to submit safety data, including information on any adverse events, with due analysis every 15 days for the initial two months. Later, the COVAXIN maker will be required to submit data on a monthly basis for five months.

    COVAXIN, Cobevax currently used for other age groups

    To note, Bharat Biotech's COVAXIN vaccine is currently being administered in the country to adolescents aged between 15 to 18 years. It is also the first anti-COVID-19 vaccine that has been developed indigenously in India. Meanwhile, Biological E's Corbevax, which is another indigenously developed vaccine, is being provided to those between the ages of 12 and 14 at present.

    ZycovD vaccine also approved for those above 12

    Meanwhile, Zydus Cadila's two-dose ZycovD vaccine was also approved for children over the age of 12 on Tuesday. Until Tuesday, Corbevax was the only vaccine approved for children aged 12 to 14, while Serum Institute of India's Covovax received emergency approval for the 12-17 age group. Union Health Minister Mansukh Mandaviya tweeted on Tuesday that the recent vaccine approvals have strengthened India's COVID-19 fight.

    The current COVID-19 situation in India

    India on Tuesday reported 2,483 new COVID-19 cases. The active caseload currently stands at 15,636, accounting for 0.04% of the total cases. On Tuesday, India also reported 1,399 COVID-19-related fatalities. Of these, 1,347 deaths (backlog) were reconciled by Assam, reflecting the number of COVID-19-positive patients who died due to other reasons. Meanwhile, the country's COVID-19 recovery rate stood at 98.75%.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Drugs Controller General of India
    COVID-19 Vaccine
    COVAXIN
    COVID-19 Vaccination

    Drugs Controller General of India

    COVAXIN likely to get approval for children above 2yrs: Report COVID-19
    Biological E's Corbevax vaccine approved for children aged 12-18 years COVID-19
    COVAXIN, Covishield will now be available in hospitals and clinics COVID-19
    New anti-COVID drug may cost up to Rs. 3,000: Report World Bank

    COVID-19 Vaccine

    Government considering COVID-19 booster dose for all adults: Report COVID-19
    COVID-19 vaccination for 12-14 years begins; here's how to register COVID-19
    COVID-19 vaccination for 12-14-year-olds to start from Wednesday: Details here COVID-19
    COVID-19 oral vaccine's clinical trial to begin in India soon Union Health Ministry

    COVAXIN

    COVAXIN supply to be increased as teens get COVID-19 vaccines COVID-19
    COVAXIN found 50% effective against COVID-19 in first real-world study COVID-19
    UK to add COVAXIN to approved vaccines from November 22 World Health Organization
    COVID-19: India reports 11K new cases, 526 more deaths Coronavirus

    COVID-19 Vaccination

    COVID-19: India reports 2,483 new cases, 1,399 more deaths COVID-19
    COVID-19: India reports 2,541 new cases, 30 more deaths COVID-19
    COVID-19: India reports 2,593 new cases, 44 more deaths Delhi
    COVID-19: India logs 2,527 new cases, 33 more deaths COVID-19

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023